Strategic leadership With new CEO Myles Greenberg appointed in December 2024 and prior CFO hire, InCarda Therapeutics signals a leadership transition aligned with acceleration in fundraising, partnerships, and clinical execution—an opportunity to engage in strategic collaborations, advisory roles, or co-development discussions.

Clinical momentum Active progression in RESTORE-1 Phase 3 for InRhythm and prior Phase 2 results on orally inhaled flecainide indicate a credible path to market for rapid, inhaled therapy for atrial fibrillation—target academic centers and hospital systems to discuss adoption pathways and payer considerations.

Financial posture Private company with a recent funding level around $78M and modest annual revenue in the low single-digit millions; opportunities exist for strategic investors, grant-enabled collaborations, or service partnerships to support late-stage development and commercialization activities.

Remote capabilities Partnership with remote patient monitoring expert physIQ demonstrates openness to digital health integration; pursue ventures around telemedicine, at-home treatment workflows, real-time monitoring, and data analytics to support patient safety and adherence programs.

Strategic partnerships Existing focus on cardiovascular therapies with academic and conference activity suggests receptivity to industry collaborations, CRO/CMO support, and co-development or licensing deals to accelerate clinical milestones and expand reach across care settings.